Tysabri (Natalizumab) Infusion: Balancing Powerful MS Relief Against a Rare but Serious Risk

Tysabri (natalizumab) is one of the most effective infusion therapies available for relapsing multiple sclerosis, reducing relapses by approximately 68% in clinical trials. However, it carries a rare but potentially life-threatening risk of progressive multifocal leukoencephalopathy (PML), a brain infection. This tension between remarkable effectiveness and serious risk makes Tysabri one of the most carefully monitored medications in neurology.

What Is Tysabri and How Does It Work?

Tysabri belongs to a class of drugs called integrin receptor antagonists. In simpler terms, it works by blocking certain immune cells from crossing from the bloodstream into the brain and spinal cord. Think of it as placing a barrier at a doorway — the immune cells that would normally enter the central nervous system and cause damage in MS are physically prevented from getting through.

The drug targets a protein called alpha-4 integrin on the surface of immune cells. By attaching to this protein, Tysabri stops those cells from latching onto blood vessel walls and migrating into brain tissue, where they would otherwise attack the protective myelin coating around nerve fibers.

FDA-Approved Conditions

Tysabri holds FDA approval for two conditions:

• Relapsing forms of multiple sclerosis (MS) — including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is generally reserved for patients who have had an inadequate response to, or cannot tolerate, other MS therapies.
• Moderate to severe Crohn’s disease — for adults who have not responded adequately to conventional therapies and TNF-alpha inhibitors. It is not approved as first-line Crohn’s treatment.

For both conditions, Tysabri is typically considered after other treatments have been tried, largely because of the PML risk. However, some neurologists may recommend it earlier for patients with highly active, aggressive MS when the benefit of rapid disease control outweighs the risk.

Why Patients Choose Tysabri Despite the Risks

The clinical data behind Tysabri is striking. In the landmark AFFIRM trial, Tysabri reduced the rate of clinical relapses by 68% compared to placebo and reduced the risk of sustained disability progression by 42% over two years. Many patients report feeling noticeably better within the first few months of treatment — a speed of response that not all MS therapies deliver.

For people living with aggressive relapsing MS — those experiencing frequent relapses, accumulating disability, or showing significant new lesions on MRI — the calculus often tips toward Tysabri. When disease activity is high, the concrete and present danger of MS progression can outweigh the small statistical risk of PML.

Beyond the numbers, many patients describe Tysabri as the treatment that gave them their lives back. The once-monthly schedule is also more manageable than some alternatives that require more frequent dosing or daily pills with their own side effect profiles.

Understanding PML Risk and JC Virus Testing

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection caused by the John Cunningham (JC) virus. Most people are exposed to this common virus during childhood and carry it harmlessly. However, when the brain’s immune surveillance is reduced — as it is with Tysabri — the JC virus can reactivate and cause damage to the brain’s white matter.

How JC Virus Risk Is Stratified

Not everyone on Tysabri faces the same PML risk. The risk stratification system works like this:

Patients who are JC virus antibody-negative have an estimated PML risk of approximately 0.1 per 1,000 or lower. For JC virus antibody-positive patients with a high antibody index, no prior immunosuppressant use, and more than two years of treatment, the risk may rise to approximately 6-10 per 1,000. These numbers help neurologists and patients make informed decisions together.

The TOUCH Prescribing Program

Tysabri is available only through a restricted distribution program called the TOUCH (Tysabri Outreach: Unified Commitment to Health) Prescribing Program. This is an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) designed to minimize PML risk.

Under the TOUCH program:

• Prescribers must be registered and complete training on Tysabri’s risks
• Patients must read a medication guide and sign an enrollment form acknowledging they understand the PML risk
• Infusion centers must be registered with the program
• Every infusion requires reauthorization — patients cannot simply refill like a standard prescription
• JC virus antibody testing is required every six months

While the extra steps can feel burdensome, the TOUCH program has been credited with improving early PML detection and keeping patients safer through consistent monitoring.

What to Expect During Infusion

Tysabri infusions are given once every four weeks (28 days). Each infusion typically takes about one hour, followed by an observation period of at least one hour afterward. Most people find the infusion itself comfortable and uneventful.

Here is a typical visit timeline:

1. Check-in and vitals (10-15 minutes): Blood pressure, temperature, and a brief symptom review
2. IV access and infusion start (about 1 hour): The medication is administered through a standard IV line
3. Post-infusion observation (1 hour): Monitoring for allergic or hypersensitivity reactions, which are most likely to occur during or shortly after infusion

Unlike some infusion therapies, Tysabri does not typically require premedication with steroids or antihistamines, though some infusion centers may offer them if a patient has a history of mild infusion reactions.

Common and Serious Side Effects

Common Side Effects

• Headache
• Fatigue
• Joint pain
• Urinary tract infections
• Upper respiratory infections
• Mild infusion-related reactions (flushing, nausea, dizziness)

Serious Side Effects

• PML — the most significant risk, discussed above
• Liver injury — signs include jaundice, dark urine, or unexplained nausea; liver function tests should be monitored
• Allergic reactions — can occur during or within one hour after infusion; more common in patients who have developed anti-natalizumab antibodies
• Herpes infections — including herpes encephalitis and meningitis, though these are rare

Tysabri vs. Other MS Therapies

Neurologists consider several factors when choosing between Tysabri and other high-efficacy MS treatments like Ocrevus (ocrelizumab) or Rituxan (rituximab):

One often-overlooked advantage of Tysabri is its relative reversibility. Because it does not destroy immune cells but rather blocks their movement, its effects begin wearing off within weeks of stopping treatment. This can be an important consideration for women planning pregnancy or patients who need to switch therapies quickly.

Home Infusion Options

Some patients may be eligible for Tysabri home infusion after completing several uneventful infusions at a clinic or infusion center. Home infusion can significantly reduce the time and travel burden of monthly visits. However, the TOUCH program requirements still apply — all monitoring, reauthorization, and observation protocols must be followed regardless of the infusion setting.

Not all insurance plans cover home infusion for Tysabri, and not all home infusion providers are set up to administer it. Patients interested in this option should discuss it with their neurologist and check their insurance coverage early in the process.

For a broader look at MS infusion therapy delivered at home, see the guide on MS home infusion.